NP 137

Drug Profile

NP 137

Alternative Names: NP-137

Latest Information Update: 30 Jan 2017

Price : $50

At a glance

  • Originator Netris Pharma
  • Class Monoclonal antibodies
  • Mechanism of Action Netrin 1modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Jan 2017 Phase-I clinical trials in Solid tumours (Metastatic disease, Second-line therapy or greater) in France (IV)
  • 09 Dec 2016 Preclinical trials in Solid tumours in France (IV) before December 2016
  • 25 Nov 2016 Netris Pharma plans a phase I trial for Solid tumours (Late-stage disease, Metastatic Disease) in France (NCT02977195)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top